WO2019208956A1 - Pharmaceutical composition for prevention or treatment of cognitive impairment due to aging comprising pu-erh tea extract as active ingredient - Google Patents

Pharmaceutical composition for prevention or treatment of cognitive impairment due to aging comprising pu-erh tea extract as active ingredient Download PDF

Info

Publication number
WO2019208956A1
WO2019208956A1 PCT/KR2019/004230 KR2019004230W WO2019208956A1 WO 2019208956 A1 WO2019208956 A1 WO 2019208956A1 KR 2019004230 W KR2019004230 W KR 2019004230W WO 2019208956 A1 WO2019208956 A1 WO 2019208956A1
Authority
WO
WIPO (PCT)
Prior art keywords
aging
cognitive impairment
disease
impairment due
pharmaceutical composition
Prior art date
Application number
PCT/KR2019/004230
Other languages
French (fr)
Korean (ko)
Inventor
정지현
장준호
김영환
Original Assignee
주식회사 비엔에이치리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 비엔에이치리서치 filed Critical 주식회사 비엔에이치리서치
Publication of WO2019208956A1 publication Critical patent/WO2019208956A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts
    • A23V2250/214—Tea

Definitions

  • the present invention relates to a pharmaceutical composition for preventing or treating cognitive impairment due to aging, or to a functional food for improving cognitive impairment due to aging, including an extract of Voy tea as an active ingredient.
  • the elderly aged 65 or older in Korea showed a rapid aging society with 13.8% of the total population.
  • the aged aged 65 or older are expected to reach 47.7% in 2045. It is estimated to be near (statistical agency, 2017; forecast of future households: 2015 ⁇ 2045).
  • the Aging World 2015 report released by the US Census Bureau in 2016, also forecasts that the proportion of Koreans aged 65 or over will be 35.9% in 2050 (2nd in the world after Japan among 141 countries). Korea reported the fastest aging population in the world.
  • LTP Long-term potentiation
  • EPP excitatory postsynaptic potential
  • Degradation of memory and learning is one of the functional changes in the brain caused by aging. As aging progresses, the synaptic density between hippocampal neurons decreases rapidly. As a result, synaptic plasticity is also markedly degraded, as aging progresses and requires greater stimulation to induce LTP (Barnes et al., 2000) or more readily falls into LTD (Tombaugh et al., 2002). Moore et al., 1993), and this decrease in LTP has been reported as a major cause of senile cognitive decline.
  • Pu'er tea is a type of post-fermented black tea that has been consumed by ethnic minorities in China. Because tea produced in various provinces is collected and shipped from the Puer County tea market, it is named "Fuer Tea”. As it gets older, the astringent taste disappears, and the aroma lasts longer. The color of the leaves is changed from pale red to deep red.
  • Korean Patent Publication No. 10-1108216 discloses a pharmaceutical composition for antimicrobial containing ivory tea water extract as an active ingredient
  • Republic of Korea Patent Publication No. 10-1111533 discloses a cosmetic composition for whitening containing a tea extract, black garlic extract and bark extract
  • Korean Patent Publication No. 10-0443116 has disclosed a tea composition exhibiting anti-obesity and anti-cholesterol effect.
  • the present inventors completed the present invention by newly observing that Voj tea, which has been used in antibacterial and anti-obesity, has a significant effect on improving senile deterioration.
  • an object of the present invention is to provide a functional food for improving cognitive impairment due to aging, including the ivory tea extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for preventing or treating cognitive impairment due to aging, including the extract tea.
  • the cognitive function is perception, memory, attention, speech comprehension, speech generation, reading comprehension, image creation It may be selected from the group consisting of imagery, learning and reasoning.
  • the cognitive impairment may be a degenerative brain disease
  • the degenerative brain disease may be selected from Alzheimer's disease, Parkinson's disease, hunting tongue disease, tau disease and stroke.
  • the present invention also provides a functional food for improving cognitive impairment due to aging, including the extract of Voy tea as an active ingredient.
  • the present invention by the above-mentioned problem solving means can provide a novel pharmaceutical composition or functional food comprising the vocha tea extract as an active ingredient, it can effectively suppress and treat cognitive impairment caused by aging.
  • Figure 1 shows the result of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment of the distilled water vehicle in the hippocampus section of adult mice (week 10).
  • Figure 2 shows the result of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment of the distilled water carrier in the hippocampus section of old age (16 months) mice.
  • Figure 3 shows the results of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment with Bochacha extract in hippocampal sections of old age (16 months) mice.
  • Figure 4 is a graph showing the average value of the relative comparison (% of baseline) fEPSP size before and after TBS.
  • the present invention relates to a pharmaceutical composition for preventing or treating cognitive impairment due to aging, comprising the extract of Voy tea as an active ingredient.
  • Black tea is a post-fermented tea of the black tea family that naturally ferments the cheongchacha tea processed with Camellia sinensis LINNE in Yunnan, China under high pressure or acid tea.
  • Boicha has been popular because it is effective in preventing obesity because of its ability to decompose fat, but there is no known cognitive improvement due to aging.
  • the Chinese text, Boncho River Moth Tea is said to have a unique scent, and it has the effect of relieving hangovers and digestion, cutting phlegm, clearing the stomach, quenching thirst and removing greasy fat.
  • the boy tea since the boy tea has no side effects even after long-term use, it is called beauty tea, diet tea, and longevity tea in Japan, France, Germany, Italy, and Macau (Son et al., Food & Nutr. 18: 219-224 , 2005).
  • Voy tea extract in the present invention may be in the form of an extract extracted with water or a solvent using a method commonly used in the art.
  • Voy tea extract the active ingredient of the present invention, is a natural substance that is harmless to the human body, which is consumed as tea, so it has little toxicity and side effects, so it can be used safely even for long-term use. Especially, it can be safely applied to pharmaceutical and food compositions. Can be.
  • the LTP measured in the Schaffer collateral-CA1 circuit of the rats of Bocha extract in old age (16 months) was decreased compared with the LTP measured in adulthood (10 weeks).
  • LTP reduced by aging can be restored to normal adult level by the Voy tea extract. That is, it was experimentally confirmed that the Bocha extract has activity for the treatment, prevention and improvement of cognitive impairment due to aging.
  • the cognitive function is perception, memory, attention, speech comprehension, speech generation, reading comprehension, image creation It refers to cognitive functions that can be degraded due to natural aging such as imagery, learning, reasoning, etc.
  • the cognitive impairment due to aging may be a degenerative brain disease.
  • the degenerative brain diseases include Alzheimer's disease, Parkinson's disease, hunting tongue disease, tau disease, stroke and the like.
  • Alzheimer's disease means a disease involving mental degeneration associated with certain degenerative brain diseases characterized by senile plaques, neuroinflammatory tangles, and progressive neuronal loss.
  • Parkinson's disease refers to chronic and progressive degenerative diseases of the central nervous system that often impair motor and speech. Parkinson's disease belongs to a group of conditions called motor disorders and is characterized by muscle stiffness, tremors, slowness of movement, and in severe cases loss of physical exercise.
  • Huntington's disease refers to a neurodegenerative disease caused by three-base repeated expansion in a gene encoding Huntington's protein, accompanied by chorea, psychosis, dementia and the like.
  • tau disease refers to a neurodegenerative disorder in which the brain nerve is damaged by accumulation of altered tau proteins (family closely related to intracellular microtubule-related proteins).
  • stroke refers to a condition in which a partially or totally rapid disorder of brain function lasts for a considerable period of time, and no cause can be found other than cerebrovascular disease.
  • the pharmaceutical composition according to the invention may comprise a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
  • the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
  • a lubricant e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, a kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mann
  • compositions of the present invention may be oral or parenteral, and parenteral administration includes intravenous infusion, subcutaneous infusion, intramuscular injection, intraperitoneal injection, transdermal administration and the like.
  • composition according to the invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to the type, severity, and activity of the patient's disease. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts.
  • the composition according to the present invention may be administered as a separate therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
  • the effective amount of the composition according to the present invention may vary depending on the age, sex and weight of the patient, and generally 0.001 to 150 mg, preferably 0.01 to 100 mg per 1 kg of body weight is administered daily or every other day or 1 to 1 day. It can be divided into three doses. However, the dosage may be increased or decreased depending on the route of administration, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
  • compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporating into a multi-dose container.
  • the formulation may be in the form of a solution, suspension or emulsion in an oil or an aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer.
  • active ingredients in the compositions of the present invention are not only the tea extract itself, but also its pharmaceutically acceptable salts, hydrates, solvates or prodrugs.
  • the present invention also relates to a functional food for improving the cognitive impairment due to aging containing the ivory tea extract as an active ingredient.
  • the functional food is not particularly limited, and may be, for example, beverages, gums, teas, vitamin complexes, health supplements, and more specifically, dairy products, confectionery, seasonings, beverages and drinks, snacks, candy, jelly. , Ice cream and frozen desserts, breakfast cereals, nutrition bars, snack bars chocolate products, processed foods, grain products and pastas, soups, sauces and dressings, confectionery products, oils and fats products, dairy drinks and milk drinks, Tea, soy milk and soy dairy-like products, frozen foods, cooked foods and substitutes, meat products, cheese, yogurt, bread and buns, cakes, cookies and crackers.
  • the functional food may be prepared in the form of capsules, tablets, powders, liquid suspensions, pills and granules containing the vocha tea extract.
  • the functional food in addition to the ivory tea extract may further include ingredients that are commonly added at the time of food production as an active ingredient.
  • Functional foods of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and salts thereof , Organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agent used in carbonated drinks, and the like, and may contain fruit juice or pulp for preparing vegetable drinks.
  • mice Male C57BL / 6 mice Experimental mice were stored in cages divided into groups of 3 to 4 individuals, and were kept in a light / dark cycle condition of 12 hours in a constant temperature and humidity facility freely provided with water and food until the experiment.
  • Hippocampal slices used for electrophysiological experiments were prepared in adult (10 weeks) and old age (16 months) rats, respectively, and only one electrophysiology experiment was performed on one section.
  • the artificial cerebrospinal fluid was intra-cardiac whole body perfusion through the heart, and the brain was rapidly removed while the rat was anesthetized (isoflurane 2%).
  • composition and conditions of artificial cerebrospinal fluid are as follows:
  • a brain tissue block including a hippocampal region was prepared, and hippocampal sections were prepared by cutting 400 ⁇ m thick in a coronal section direction using a vibratome (Leica VT 1000S).
  • the prepared hippocampal sections were transferred to artificial cerebrospinal fluid at 35 ° C and supplied with oxygen, followed by recovery for 30 minutes, and then incubated for 1 hour in room temperature Voycha extract (10 ⁇ g / ml distilled water) or distilled water vehicle (carrier). Immediately used for electrophysiology experiments.
  • Boi tea extract (Jen M Life Co., Ltd., China tea leaf 100%, powder) was purchased from the market and stored at room temperature, dissolved in distilled water immediately before the experiment was used diluted to the final working concentration (10 ⁇ g / ml). Distilled water in which the tea extract was dissolved was used as a vehicle for the control experiment.
  • Hippocampal sections were transferred to a submersion chamber for electrophysiology experiments, where artificial cerebrospinal fluid at 31 ⁇ 0.5 ° C. was perfused at a rate of 2 ml / minute.
  • Surgical excision before LTP measurement was performed to independently secure the Schaffer collateral-CA1 neural circuit region, which excludes interference with other neurons.
  • the CA1 region of the hippocampus connects with Schaffer collateral, an axon of pyramidal cells in the CA3 region, and receives information.
  • This Schaffer collateral-CA1 neural circuit plays an important role in memory formation. It has been reported to be the most widely used in LTP measurement experiments in the hippocampus.
  • a recording pipette (resistance value of 3-6 M ⁇ ) is placed on the CA1 stratum radiatum and the whole cell from the neuron.
  • FEPSP field EPSP
  • the electrical stimulation for fEPSP generation was performed by bipolar stimulating electrode located in the Schaffer collateral, and the stimulation electrode was located 200-300 ⁇ m away from the measuring pipette.
  • Baseline was established by measuring fEPSP at CA1 produced by Schaffer collateral electrical stimulation (0.1 Hz, 0.2 ms duration) for the first 20 minutes, and then theta burst stimulation (TBS) stimulation (100 Hz, 0.2 ms duration, 8 times).
  • fEPSP 0.1 Hz, 0.2 ms duration
  • TBS burst stimulation
  • fEPSP was measured for 1 hour in the same manner as the protocol used for baseline fEPSP measurement (0.1 Hz, 0.2 ms duration), and the level of LTP was confirmed by comparing the value with the baseline (%).
  • the intensity of the electrical stimulation was used to obtain the current intensity to generate 50% of the maximum fEPSP value for each experiment.
  • the fEPSP electrical signal was converted to a digital signal through an axopatch 1D amplifier and recorded and analyzed on a computer using the Digidata 1322A acquisition system and AXON TM pClamp 9.0 software.
  • Figure 1 shows the results of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment of distilled water vehicle in hippocampus sections of adult rats (week 10).
  • the size of the fEPSP after TBS is significantly increased (% of baseline) compared to the size of the baseline fEPSP before TBS, it can be seen that LTP induced long-term strengthening of synapses.
  • the fEPSP trace inserted at the top of the graph shows the average fEPSP (black line) for the initial 20 minutes and the average fEPSP (red line) for 1 hour after TBS.
  • Figure 2 is a result of measuring the fEPSP produced in CA1 by the Schaffer collateral stimulation after treatment of distilled water vehicle in hippocampus sections of the elderly rats (16 months).
  • the size of fEPSP after TBS is relatively increased (% of baseline) compared to the size of the baseline fEPSP before TBS can be confirmed that the LTP was induced, but induced in normal adulthood (10 weeks) Compared with LTP, the degree of generation is low, so it is possible to check the deterioration state in old age.
  • Figure 3 is a result of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment with Bocha tea extract (10 ⁇ g / ml) dissolved in distilled water in the hippocampus section of the experimental rats (16 months old age).
  • LTP measured in old-age hippocampus treated with vocha tea extract was greater than LTP measured in old-time hippocampus treated with distilled water vehicle, and recovered to no difference compared to normal adulthood (10 weeks). It can confirm the improvement effect of cognitive deterioration by senescence.
  • fEPSP measured in the group treated with the boy tea extract in the old age (16 months) hippocampus was statistically significantly increased compared to the old age (16 months) group treated with the vehicle. 10 weeks) was not statistically different from the group. This means that it has been confirmed electro-biologically that the ivory tea extract has an effect of improving senile deterioration to normal levels in adulthood.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of cognitive impairment due to aging comprising pu-erh tea extract as an active ingredient. The present invention can effectively suppress and treat cognitive impairment due to natural aging by providing a novel pharmaceutical composition and functional food containing the pu-erh tea extract as an active ingredient.

Description

보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물Pharmaceutical composition for the prevention or treatment of cognitive impairment due to aging comprising the extract as an active ingredient
본 발명은 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물, 또는 노화로 인한 인지기능 장애 개선용 기능성 식품에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating cognitive impairment due to aging, or to a functional food for improving cognitive impairment due to aging, including an extract of Voy tea as an active ingredient.
국내 통계청 자료에 따르면 2017년 한국의 65세 이상 고령자는 전체 인구의 13.8%로 이미 급속한 고령화 사회로 진입하였음을 보여주며, 현 추세대로 노령화가 진행될 시 2045년에는 65세 이상 고령화 가구가 47.7%에 육박할 것으로 추산하고 있다(통계청, 2017; 장래가구추계: 2015~2045년). 미국 통계국이 2016년 발표한 '늙어가는 세계 2015' 보고서(The Aging World: 2015) 역시 2050년 한국의 65세 이상 인구 비율을 35.9%(141개 조사 대상국 중 일본에 이어 세계 2위)로 예상하고 있으며, 한국의 고령화 속도가 세계에서 가장 빠른 것으로 보고하였다.According to the statistics of the National Statistical Office, in 2017, the elderly aged 65 or older in Korea showed a rapid aging society with 13.8% of the total population.In aging population, the aged aged 65 or older are expected to reach 47.7% in 2045. It is estimated to be near (statistical agency, 2017; forecast of future households: 2015 ~ 2045). The Aging World 2015 report, released by the US Census Bureau in 2016, also forecasts that the proportion of Koreans aged 65 or over will be 35.9% in 2050 (2nd in the world after Japan among 141 countries). Korea reported the fastest aging population in the world.
노화가 진행됨에 따라 정보 처리 및 학습, 지각, 추론, 문제해결 및 기억 등을 포함하는 인지기능의 저하가 자연적으로 나타나는데, 노화가 급속하게 진행되는 노년기에는 다른 연령대에 비해서 인지저하가 더욱 두드러지게 나타난다. 노인의 신체기능 저하는 노화 현상과 복합적으로 작용하여 뇌기능에 부정적 영향을 미치며, 뇌 기능 저하는 심각한 인지 저하를 유발하여 정상적인 일상생활을 유지할 수 없게 한다. 노인성 인지 저하는 결국 개인을 사회활동으로부터 고립시키고 노년기 삶의 질을 심각하게 훼손하는 결과를 초래하게 된다.As aging progresses, cognitive decline naturally occurs, including information processing and learning, perception, reasoning, problem solving, and memory.In older age, the cognitive decline is more pronounced than in other ages. . Degradation of physical function of the elderly acts in combination with the aging phenomenon negatively affects the brain function, brain deterioration causes severe cognitive decline can not maintain normal daily life. Geriatric cognitive decline eventually results in isolating individuals from social activities and severely undermining old age quality of life.
인지기능 중 기억과 학습은 주로 해마(hippocampus), 치아이랑(dentate gyrus) 및 해마이행부(subiculum)로 구성된 해마형성체(hippocampal formation)에서 형성되는 것으로 알려져 있는데, 해마형성체에 위치한 특정 신경세포를 고주파 전류로 반복해서 자극하였을 때 시냅스(synapse)로 연결된 인접 신경세포에서 EPSP(excitatory postsynaptic potential; 흥분성 연접후 전위)가 장기간 증가하는 LTP(long-term potentiation; 장기강화작용) 현상이 보고되었다. 이러한 LTP 현상은 시냅스로 연결되어 있는 인근 신경세포와의 대화능력이 강화됨을 의미하며, LTP의 반대현상인 LTD(long-term depression; 장기저하작용)와 함께 기억/학습 및 망각의 생리학적 기전으로 받아들여지고 있다(Nature, 511, 348-352, 2014).Memory and learning of cognitive function are known to be formed in hippocampal formation, which is mainly composed of hippocampus, dental gyrus and hippocampus. Long-term potentiation (LTP) has been reported in which long-term increases in excitatory postsynaptic potential (EPSP) occur in adjacent neurons connected by synapses when repeated with high frequency currents. This LTP phenomenon means that the ability to communicate with neighboring neurons connected by synapses is strengthened, and it is a physiological mechanism of memory / learning and forgetting along with LTD (long-term depression), which is the opposite of LTP. It is accepted (Nature, 511, 348-352, 2014).
기억 및 학습능력의 저하는 노화에 의해 발생하는 뇌의 기능적 변화 중 하나인데, 노화가 진행됨에 따라 해마 신경세포들 간의 시냅스 밀도(synaptic density)가 급격히 감소하는 것으로 알려져 있다. 이에 따라 시냅스 가소성(synaptic plasticity) 능력 역시 현저히 저하되는데, 노화가 진행됨에 따라 LTP를 유발시키는데 더 큰 자극이 필요하거나(Barnes et al., 2000) 더 쉽게 LTD로 빠지게 되며(Tombaugh et al., 2002; Moore et al., 1993), 이러한 LTP의 감소는 노인성 인지기능 저하의 주요 원인으로 보고되었다.Degradation of memory and learning is one of the functional changes in the brain caused by aging. As aging progresses, the synaptic density between hippocampal neurons decreases rapidly. As a result, synaptic plasticity is also markedly degraded, as aging progresses and requires greater stimulation to induce LTP (Barnes et al., 2000) or more readily falls into LTD (Tombaugh et al., 2002). Moore et al., 1993), and this decrease in LTP has been reported as a major cause of senile cognitive decline.
급속한 노령화 및 고연령층의 기대수명 증가는 삶의 질에 대한 사회적 관심 증가와 더불어 건강하게 오래 살고자 하는 요구를 증폭시키고 있으며, 이에 따라 노인성 인지기능 저하를 개선 및 예방할 수 있는 건강식품 및 약물 개발이 절실히 요구되고 있다. 현재 노인성 인지 저하를 개선하기 위한 약물 및 건강식품들이 일부 나와있으나 알츠하이머와 같은 특정 노인성 질병에 편중되어 있어, 자연적 노화에 의한 인지 저하를 효과적으로 개선할 수 있는 활성물질의 지속적인 탐색이 요구되고 있다.The rapid aging and increase in life expectancy of older people are amplifying the need to live longer and healthier as well as increasing social interest in quality of life. Accordingly, there is an urgent need to develop health foods and drugs that can improve and prevent senile cognitive decline. It is required. Currently, there are some drugs and health foods for improving senile cognitive deterioration, but they are focused on certain senile diseases such as Alzheimer's disease, and thus, there is a need for continuous search for active substances that can effectively improve cognitive deterioration due to natural aging.
한편, 보이차(Pu'er tea)는 중국 변방의 소수민족들이 마시기 시작한 것으로 후발효 흑차의 일종이다. 여러 지방에서 생산된 차를 푸얼현 차시장에서 모아 출하하기 때문에, 푸얼차라는 이름이 붙었다. 오래되면 될수록 떫은 맛이 사라지며, 향기가 오래 지속되는 특징이 있다. 잎을 우려낸 색깔은 옅은 홍색에서 세월이 지날 수록 심홍색 계통으로 변해간다.Pu'er tea, on the other hand, is a type of post-fermented black tea that has been consumed by ethnic minorities in China. Because tea produced in various provinces is collected and shipped from the Puer County tea market, it is named "Fuer Tea". As it gets older, the astringent taste disappears, and the aroma lasts longer. The color of the leaves is changed from pale red to deep red.
보이차를 의약/화장품 용도로 사용한 예로는, 대한민국 등록특허공보 제10-1108216호에서 보이차 물 추출물을 유효성분으로 포함하는 항균용 의약 조성물을 개시하고 있고, 대한민국 등록특허공보 제10-1111533호에서 보이차 추출물, 흑마늘 추출물 및 목단피 추출물을 함유하는 미백용 화장료 조성물을 개시하고 있으며, 대한민국 등록특허공보 제10-0443116호에서는 항비만 및 항콜레스테롤 효과를 나타내는 보이차 조성물을 개시한 바 있다.As an example of using ivory tea as a medicine / cosmetic use, Korean Patent Publication No. 10-1108216 discloses a pharmaceutical composition for antimicrobial containing ivory tea water extract as an active ingredient, and Republic of Korea Patent Publication No. 10-1111533 In the present invention discloses a cosmetic composition for whitening containing a tea extract, black garlic extract and bark extract, Korean Patent Publication No. 10-0443116 has disclosed a tea composition exhibiting anti-obesity and anti-cholesterol effect.
본 발명자들은 종래 항균, 항비만 등에 사용되던 보이차가 노인성 인지저하 개선에 유의미한 효과를 나타낸다는 것을 새롭게 관찰하고 본 발명을 완성하였다.The present inventors completed the present invention by newly observing that Voj tea, which has been used in antibacterial and anti-obesity, has a significant effect on improving senile deterioration.
본 발명의 목적은 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물을 제공하는 것이다.It is an object of the present invention to provide a pharmaceutical composition for preventing or treating cognitive dysfunction due to aging, comprising the extract of Voy tea as an active ingredient.
또한, 본 발명의 목적은 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 개선용 기능성 식품을 제공하는 것이다.In addition, an object of the present invention is to provide a functional food for improving cognitive impairment due to aging, including the ivory tea extract as an active ingredient.
이와 같은 목적을 달성하기 위하여, 본 발명은 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating cognitive impairment due to aging, including the extract tea.
본 발명에 있어서, 상기 인지기능은 지각(perception), 기억(memory), 주의(attention), 언어 이해(speech comprehension), 언어 생성(speech generation), 독서 이해(reading comprehension), 심상 생성(creation of imagery), 학습(learning) 및 추리(reasoning)로 이루어지는 군에서 선택될 수 있다.In the present invention, the cognitive function is perception, memory, attention, speech comprehension, speech generation, reading comprehension, image creation It may be selected from the group consisting of imagery, learning and reasoning.
본 발명에서, 상기 인지기능 장애는 퇴행성 뇌질환일 수 있으며, 상기 퇴행성 뇌질환은 알츠하이머병, 파킨슨병, 헌팅텅병, 타우병증 및 뇌졸중에서 선택될 수 있다.In the present invention, the cognitive impairment may be a degenerative brain disease, the degenerative brain disease may be selected from Alzheimer's disease, Parkinson's disease, hunting tongue disease, tau disease and stroke.
본 발명은 또한, 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 개선용 기능성 식품을 제공한다.The present invention also provides a functional food for improving cognitive impairment due to aging, including the extract of Voy tea as an active ingredient.
상기와 같은 과제해결수단에 의한 본 발명은 보이차 추출물을 유효성분으로 포함하는 신규한 약제학적 조성물 또는 기능성 식품을 제공함으로써, 노화로 인한 인지기능 장애를 효과적으로 억제하고 치료할 수 있다.The present invention by the above-mentioned problem solving means can provide a novel pharmaceutical composition or functional food comprising the vocha tea extract as an active ingredient, it can effectively suppress and treat cognitive impairment caused by aging.
도 1은 성인기(10주) 실험쥐의 해마 절편에 증류수 운반체를 처리한 후 Schaffer collateral 자극에 의해 CA1에서 생성되는 fEPSP를 측정한 결과를 나타낸다.Figure 1 shows the result of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment of the distilled water vehicle in the hippocampus section of adult mice (week 10).
도 2는 노년기(16개월) 실험쥐의 해마 절편에 증류수 운반체를 처리한 후 Schaffer collateral 자극에 의해 CA1에서 생성되는 fEPSP를 측정한 결과를 나타낸다.Figure 2 shows the result of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment of the distilled water carrier in the hippocampus section of old age (16 months) mice.
도 3은 노년기(16개월) 실험쥐의 해마 절편에 보이차 추출물을 처리한 후 Schaffer collateral 자극에 의해 CA1에서 생성되는 fEPSP를 측정한 결과를 나타낸다.Figure 3 shows the results of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment with Bochacha extract in hippocampal sections of old age (16 months) mice.
도 4는 TBS 전후의 fEPSP 크기를 상대적으로 비교한(% of baseline) 평균값을 나타낸 그래프이다.Figure 4 is a graph showing the average value of the relative comparison (% of baseline) fEPSP size before and after TBS.
이하, 본 발명의 구체적인 양태에 대해서 보다 상세히 설명한다. 다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 갖는다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술 분야에서 잘 알려져있고 통상적으로 사용되는 것이다.Hereinafter, the specific aspect of this invention is demonstrated in detail. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is well known and commonly used in the art.
본 발명은 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물에 관한 것이다. The present invention relates to a pharmaceutical composition for preventing or treating cognitive impairment due to aging, comprising the extract of Voy tea as an active ingredient.
보이차는 중국 운남의 대엽종 차나무(Camellia sinensis LINNE)로 가공한 쇄청모차를 긴압 또는 산차의 상태에서 자연발효하는 흑차계열의 후발효차이다. 보이차에는 지방분해력이 있으므로 비만 방지에 효과가 있다고 하여 인기가 있었으나, 노화로 인한 인지기능 개선에 대해서는 알려진 바가 없었다.Black tea is a post-fermented tea of the black tea family that naturally ferments the cheongchacha tea processed with Camellia sinensis LINNE in Yunnan, China under high pressure or acid tea. Boicha has been popular because it is effective in preventing obesity because of its ability to decompose fat, but there is no known cognitive improvement due to aging.
중국문헌인 본초강목십유에서는 보이차를 향이 독특하며, 숙취 해소와 소화를 돕고, 가래를 삭히고, 위를 깨끗이 하며, 갈증 해소와 우리 몸에 해로운 기름기를 제거하는 작용이 있다고 한다. 또한, 보이차는 장기간 복용하여도 부작용이 없으므로 일본, 프랑스, 독일, 이태리, 마카오 등에서는 미용차, 다이어트차, 장수차 등으로 불리어지고 있다 (Son et al., Food & Nutr. 18:219-224, 2005).The Chinese text, Boncho River Moth Tea, is said to have a unique scent, and it has the effect of relieving hangovers and digestion, cutting phlegm, clearing the stomach, quenching thirst and removing greasy fat. In addition, since the boy tea has no side effects even after long-term use, it is called beauty tea, diet tea, and longevity tea in Japan, France, Germany, Italy, and Macau (Son et al., Food & Nutr. 18: 219-224 , 2005).
본 발명에서 보이차 추출물은 업계에 일반적으로 사용되는 방법을 이용하여 물 또는 용매에 의해 추출된 추출물의 형태일 수 있다.Voy tea extract in the present invention may be in the form of an extract extracted with water or a solvent using a method commonly used in the art.
본 발명의 유효성분인 보이차 추출물은 차(茶)류로 음용되고 있는 인체에 무해한 천연 물질로서 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으며, 특히 약제학적 및 식품 조성물에 안전하게 적용할 수 있다.Voy tea extract, the active ingredient of the present invention, is a natural substance that is harmless to the human body, which is consumed as tea, so it has little toxicity and side effects, so it can be used safely even for long-term use. Especially, it can be safely applied to pharmaceutical and food compositions. Can be.
본 발명의 일 실시예에서는 보이차 추출물 노년기(16개월) 실험 쥐의 해마형성체 신경회로(Schaffer collateral-CA1 circuit)에서 측정한 LTP가 성인기(10주)에서 측정한 LTP와 비교하여 감소해 있다는 것과, 노화에 의해 감소한 LTP가 보이차 추출물에 의해 성인기 정상 수준으로 회복될 수 있다는 것을 확인하였다. 즉, 보이차 추출물이 노화로 인한 인지기능 장애의 치료, 예방 및 개선을 위한 활성을 갖는 다는 것을 실험적으로 확인하였다.According to one embodiment of the present invention, the LTP measured in the Schaffer collateral-CA1 circuit of the rats of Bocha extract in old age (16 months) was decreased compared with the LTP measured in adulthood (10 weeks). In addition, it was confirmed that LTP reduced by aging can be restored to normal adult level by the Voy tea extract. That is, it was experimentally confirmed that the Bocha extract has activity for the treatment, prevention and improvement of cognitive impairment due to aging.
본 발명에 있어서, 상기 인지기능은 지각(perception), 기억(memory), 주의(attention), 언어 이해(speech comprehension), 언어 생성(speech generation), 독서 이해(reading comprehension), 심상 생성(creation of imagery), 학습(learning), 추리(reasoning) 등 자연적인 노화로 인하여 저하될 수 있는 인지적인 기능을 의미한다.In the present invention, the cognitive function is perception, memory, attention, speech comprehension, speech generation, reading comprehension, image creation It refers to cognitive functions that can be degraded due to natural aging such as imagery, learning, reasoning, etc.
또한, 상기 노화로 인한 인지기능 장애는 퇴행성 뇌질환일 수 있다. 상기 퇴행성 뇌질환은 알츠하이머병, 파킨슨병, 헌팅텅병, 타우병증, 뇌졸중(stroke) 등이다.In addition, the cognitive impairment due to aging may be a degenerative brain disease. The degenerative brain diseases include Alzheimer's disease, Parkinson's disease, hunting tongue disease, tau disease, stroke and the like.
본 발명의 용어, "알츠하이머병"이란 노인성 플라크, 신경염증 엉킴(tangles), 및 진행성 신경 손실로 특징되는 특정 퇴행성 뇌질환과 관련된 정신적인 퇴화를 수반하는 질병을 의미한다.As used herein, the term "Alzheimer's disease" means a disease involving mental degeneration associated with certain degenerative brain diseases characterized by senile plaques, neuroinflammatory tangles, and progressive neuronal loss.
본 발명의 용어 "파킨슨병"이란 종종 운동 기능 및 언어능력을 손상시키는 중추 신경계의 만성 및 진행성 퇴행성 질환을 의미한다. 상기 파킨슨병은 운동 질환으로 불리는 상태의 군에 속하며 근육경직, 떨림, 신체움직임의 느림, 및 심각한 경우에는 신체적 운동의 손실에 의해 특징된다.As used herein, the term "Parkinson's disease" refers to chronic and progressive degenerative diseases of the central nervous system that often impair motor and speech. Parkinson's disease belongs to a group of conditions called motor disorders and is characterized by muscle stiffness, tremors, slowness of movement, and in severe cases loss of physical exercise.
본 발명의 용어 "헌팅턴병"이란 헌팅턴 단백질을 암호화하는 유전자 내 3 염기 반복 팽창에 의해 야기되어, 무도증, 정신이상, 치매 등이 수반되는 신경퇴행성 질환을 의미한다.As used herein, the term "Huntington's disease" refers to a neurodegenerative disease caused by three-base repeated expansion in a gene encoding Huntington's protein, accompanied by chorea, psychosis, dementia and the like.
본 발명의 용어 "타우병증"이란 변질된 tau 단백질(세포내 마이크로튜불-관련 단백질과 밀접하게 관련된 패밀리)이 뇌조직에 축적됨에 의하여 뇌신경이 손상되는 신경퇴행성 질환을 의미한다.As used herein, the term "tau disease" refers to a neurodegenerative disorder in which the brain nerve is damaged by accumulation of altered tau proteins (family closely related to intracellular microtubule-related proteins).
본 발명의 용어 "뇌졸중"(腦卒中)은 뇌기능의 부분적 또는 전체적으로 급속히 발생한 장애가 상당 기간 이상 지속되는 것으로, 뇌혈관의 병 이외에는 다른 원인을 찾을 수 없는 상태를 일컫는다.The term "stroke" of the present invention refers to a condition in which a partially or totally rapid disorder of brain function lasts for a considerable period of time, and no cause can be found other than cerebrovascular disease.
본 발명에 따른 약제학적 조성물은 약제학적으로 허용되는 담체를 포함할 수 있다. 상기 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다.The pharmaceutical composition according to the invention may comprise a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제화에 관해서는 레밍턴의 문헌[Remington's Pharmaceutical Sciences (19th ed., 1995)]에 개시되어 있는 방법을 이용하여 각 성분에 따라 바람직하게 제제화할 수 있다.In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. Suitable pharmaceutically acceptable carriers and formulations may be preferably formulated according to each component using the methods disclosed in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 경구 또는 비경구 투여 모두 가능하며, 비경구 투여는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등을 포함한다. The pharmaceutical compositions of the present invention may be oral or parenteral, and parenteral administration includes intravenous infusion, subcutaneous infusion, intramuscular injection, intraperitoneal injection, transdermal administration and the like.
본 발명에 따른 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 따른 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The composition according to the invention is administered in a pharmaceutically effective amount. In the present invention, “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level refers to the type, severity, and activity of the patient's disease. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts. The composition according to the present invention may be administered as a separate therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can obtain the maximum effect in a minimum amount without side effects, which can be easily determined by those skilled in the art.
구체적으로, 본 발명에 따른 조성물의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 1kg 당 0.001 내지 150mg, 바람직하게는 0.01 내지 100mg을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나 투여 경로, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Specifically, the effective amount of the composition according to the present invention may vary depending on the age, sex and weight of the patient, and generally 0.001 to 150 mg, preferably 0.01 to 100 mg per 1 kg of body weight is administered daily or every other day or 1 to 1 day. It can be divided into three doses. However, the dosage may be increased or decreased depending on the route of administration, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical compositions of the present invention may be prepared in unit dose form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporating into a multi-dose container. In this case, the formulation may be in the form of a solution, suspension or emulsion in an oil or an aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer.
본 발명의 조성물에서 유효 성분으로 이용되는 것은 보이차 추출물 자체뿐만 아니라, 그의 약제학적으로 허용 가능한 염, 수화물, 용매화물 또는 프로드러그이다.As active ingredients in the compositions of the present invention are not only the tea extract itself, but also its pharmaceutically acceptable salts, hydrates, solvates or prodrugs.
본 발명은 또한, 보이차 추출물을 유효성분으로 함유하는 노화로 인한 인지기능 장애 개선을 위한 기능성 식품에 관한 것이다.The present invention also relates to a functional food for improving the cognitive impairment due to aging containing the ivory tea extract as an active ingredient.
상기 기능성 식품은 특별히 제한되지 않으며, 예를 들어서, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류일 수 있으며, 더욱 자세히는, 유제품, 제과물, 조미료, 음료 및 드링크제, 스낵, 캔디류, 젤리류, 아이스크림 및 냉동용 디저트, 아침 곡물류, 영양바, 스낵 바 초콜렛 제품, 가공 식품, 곡물 제품 및 파스타, 스프, 소스 및 드레싱, 과자 제품, 오일 및 지방 제품, 유제품 음료 (dairy drink) 및 우유 음료, 차, 두유 및 콩 유제품 (soy dairy-like product), 냉동식품, 조리 음식 및 대체 음식, 육류 제품, 치즈, 요구르트, 빵 및 롤빵, 케이크, 쿠키 및 크래커로 이루어진 군에서 선택된 어느 하나일 수 있다.The functional food is not particularly limited, and may be, for example, beverages, gums, teas, vitamin complexes, health supplements, and more specifically, dairy products, confectionery, seasonings, beverages and drinks, snacks, candy, jelly. , Ice cream and frozen desserts, breakfast cereals, nutrition bars, snack bars chocolate products, processed foods, grain products and pastas, soups, sauces and dressings, confectionery products, oils and fats products, dairy drinks and milk drinks, Tea, soy milk and soy dairy-like products, frozen foods, cooked foods and substitutes, meat products, cheese, yogurt, bread and buns, cakes, cookies and crackers.
또한, 상기 기능성 식품은 보이차 추출물을 포함하는 캡슐, 정제, 분말, 액상 현탁액, 환제 및 과립제 등의 제형으로 제조될 수 있다.In addition, the functional food may be prepared in the form of capsules, tablets, powders, liquid suspensions, pills and granules containing the vocha tea extract.
또한, 상기 기능성 식품은 보이차 추출물을 외에도 유효성분으로서 식품 제조 시에 통상적으로 첨가되는 성분을 추가로 포함할 수 있다.In addition, the functional food, in addition to the ivory tea extract may further include ingredients that are commonly added at the time of food production as an active ingredient.
본 발명의 기능성 식품은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있으며, 과일주스나 야채 음료 제조를 위한 과육을 함유할 수 있다.Functional foods of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and salts thereof , Organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol, carbonation agent used in carbonated drinks, and the like, and may contain fruit juice or pulp for preparing vegetable drinks.
실시예Example
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only to illustrate the invention, it will be apparent to those of ordinary skill in the art that the scope of the present invention is not to be construed as limited by these examples.
실험 준비 및 방법Experiment Preparation and Methods
수컷 C57BL/6 mice 실험 쥐들을 3 내지 4 개체씩 그룹으로 나누어 케이지에 보관하였고, 실험 전까지 물과 음식이 자유롭게 제공되는 항온항습 시설에서 12시간의 빛/어둠 사이클 조건으로 사육하였다.Male C57BL / 6 mice Experimental mice were stored in cages divided into groups of 3 to 4 individuals, and were kept in a light / dark cycle condition of 12 hours in a constant temperature and humidity facility freely provided with water and food until the experiment.
전기생리학적 실험을 위해 사용된 해마 절편(hippocampal slice)은 성인기(10주) 및 노년기(16개월) 실험 쥐에서 각각 준비되었고, 하나의 절편에서는 한 번의 전기생리학 실험만 실행되었다.Hippocampal slices used for electrophysiological experiments were prepared in adult (10 weeks) and old age (16 months) rats, respectively, and only one electrophysiology experiment was performed on one section.
실험 쥐를 호흡 마취(isoflurane 2%)한 상태에서 인공 뇌척수액(artificial cerebrospinal fluid)을 심장을 통해 전신 관류(intra-cardiac whole body perfusion) 후 뇌를 신속히 적출하였다.The artificial cerebrospinal fluid was intra-cardiac whole body perfusion through the heart, and the brain was rapidly removed while the rat was anesthetized (isoflurane 2%).
인공 뇌척수액의 구성 및 조건은 다음과 같다: The composition and conditions of artificial cerebrospinal fluid are as follows:
- 195.5mM sucrose, 195.5 mM sucrose,
- 2.5mM KCl, 2.5 mM KCl,
- 2.5mM CaCl2, 2.5 mM CaCl 2 ,
- 1.3mM MgSO4, 1.3 mM MgSO 4 ,
- 1mM NaH2PO4, 1 mM NaH 2 PO 4 ,
- 26.2mM NaHCO3, 26.2 mM NaHCO 3 ,
- 11mM glucose, 11 mM glucose,
- 2mM Na pyruvate, 및2 mM Na pyruvate, and
- 1mM Na ascorbate; 1 mM Na ascorbate;
- 95% 산소 및 5% 이산화탄소 혼합가스로 포화; pH 7.4; 295-305mOsmolSaturated with 95% oxygen and 5% carbon dioxide mixed gas; pH 7.4; 295-305mOsmol
해마부위를 포함하는 뇌조직 블록(block)을 준비하고 진동절단기(vibratome; Leica VT 1000S)를 이용하여 관상면(coronal section) 방향으로 400μm 두께씩 절단함으로써 해마 절편을 제작하였다. 제작된 해마 절편들은 산소가 공급되는 35℃ 온도의 인공 뇌척수액으로 옮겨져 30분간 회복기를 거친 후 상온(room temperature)의 보이차 추출물(10μg/ml 증류수) 또는 증류수 vehicle(운반체)에 1시간 배양되었고 이후 즉시 전기생리학 실험에 사용되었다.A brain tissue block including a hippocampal region was prepared, and hippocampal sections were prepared by cutting 400 μm thick in a coronal section direction using a vibratome (Leica VT 1000S). The prepared hippocampal sections were transferred to artificial cerebrospinal fluid at 35 ° C and supplied with oxygen, followed by recovery for 30 minutes, and then incubated for 1 hour in room temperature Voycha extract (10μg / ml distilled water) or distilled water vehicle (carrier). Immediately used for electrophysiology experiments.
보이차 추출물(㈜지엔엠라이프, 중국산 차 잎 100%, 분말)은 시중에서 구입하여 상온 보관하였고, 실험 직전 증류수에 용해하여 최종 작업농도(10μg/ml)로 희석하여 사용하였다. 보이차 추출물을 용해한 증류수는 대조군 실험을 위하여 vehicle로 사용되었다.Boi tea extract (Jen M Life Co., Ltd., China tea leaf 100%, powder) was purchased from the market and stored at room temperature, dissolved in distilled water immediately before the experiment was used diluted to the final working concentration (10μg / ml). Distilled water in which the tea extract was dissolved was used as a vehicle for the control experiment.
해마 절편은 전기생리학 실험을 위해 챔버(submersion chamber)로 옮겨졌으며, 챔버에는 31±0.5℃ 온도의 인공 뇌척수액이 2ml/minute 속도로 관류되었다. LTP 측정 전 수술적 절제를 통해, 다른 신경세포와의 간섭이 배제된 Schaffer collateral-CA1 신경회로 부위를 독립적으로 확보하였다. 해마형성체의 CA1 부위는 CA3 부위에 있는 피라미드 세포(pyramidal cell)의 축삭(axon)인 Schaffer collateral과 시냅스로 연결되어 정보를 받아들이는데, 이러한 Schaffer collateral-CA1 신경회로는 기억 형성에 매우 중요한 역할을 하는 것으로 보고되어 해마에서의 LTP 측정 실험에 가장 많이 이용되고 있다.Hippocampal sections were transferred to a submersion chamber for electrophysiology experiments, where artificial cerebrospinal fluid at 31 ± 0.5 ° C. was perfused at a rate of 2 ml / minute. Surgical excision before LTP measurement was performed to independently secure the Schaffer collateral-CA1 neural circuit region, which excludes interference with other neurons. The CA1 region of the hippocampus connects with Schaffer collateral, an axon of pyramidal cells in the CA3 region, and receives information. This Schaffer collateral-CA1 neural circuit plays an important role in memory formation. It has been reported to be the most widely used in LTP measurement experiments in the hippocampus.
적외 미분간섭 현미경(infrared differential interterence contrast)을 이용해 눈으로 관찰하면서, 해마형성체 CA1 부위(CA1 stratum radiatum)에 측정피펫(recording pipette; 저항값 3-6 MΩ)을 위치시키고 해당 신경세포로부터 전체 셀 기록 모드(whole-cell recording mode)로 fEPSP(field EPSP)를 측정하였다. fEPSP 생성을 위한 전기자극은 Schaffer collateral에 위치한 양극성 자극전극(bipolar stimulating electrode)에 의해 이루어졌고, 자극전극은 측정피펫으로부터 200-300μm 거리에 위치하였다.While visually observing using an infrared differential interterence contrast, a recording pipette (resistance value of 3-6 MΩ) is placed on the CA1 stratum radiatum and the whole cell from the neuron. FEPSP (field EPSP) was measured in whole-cell recording mode. The electrical stimulation for fEPSP generation was performed by bipolar stimulating electrode located in the Schaffer collateral, and the stimulation electrode was located 200-300μm away from the measuring pipette.
최초 20분 동안 Schaffer collateral 전기자극(0.1Hz, 0.2ms duration)에 의해 생성되는 CA1에서의 fEPSP를 측정하여 기준(baseline)을 설정하였고, 이후 LTP 유도를 위해 TBS(theta burst stimulation) 자극(100Hz, 0.2ms duration, 8회)을 가하였다.Baseline was established by measuring fEPSP at CA1 produced by Schaffer collateral electrical stimulation (0.1 Hz, 0.2 ms duration) for the first 20 minutes, and then theta burst stimulation (TBS) stimulation (100 Hz, 0.2 ms duration, 8 times).
이어서, baseline fEPSP 측정에 사용된 프로토콜(0.1Hz, 0.2ms duration)과 동일한 방법으로 1시간 동안 fEPSP를 측정하고 그 값을 baseline과 상대적으로(%) 비교함으로써 LTP 생성정도를 확인하였다. 전기자극의 세기는 각각의 실험마다 fEPSP 최대값의 50%가 생성되도록 하는 전류 세기를 구하여 사용하였다.Subsequently, fEPSP was measured for 1 hour in the same manner as the protocol used for baseline fEPSP measurement (0.1 Hz, 0.2 ms duration), and the level of LTP was confirmed by comparing the value with the baseline (%). The intensity of the electrical stimulation was used to obtain the current intensity to generate 50% of the maximum fEPSP value for each experiment.
fEPSP 전기신호는 앰프(axopatch 1D amplifier)를 통해 디지털 신호로 변환되었고, Digidata 1322A acquisition system 및 AXONTM pClamp 9.0 software를 이용해 컴퓨터에 기록 및 분석하였다.The fEPSP electrical signal was converted to a digital signal through an axopatch 1D amplifier and recorded and analyzed on a computer using the Digidata 1322A acquisition system and AXON ™ pClamp 9.0 software.
실험의 통계는 one-way ANOVA를 사용하여 수행하였고, 개별 그룹간의 비교를 위해 tukey's post hoc 테스트를 추가로 시행하였다. P<0.05이 통계적으로 유의미한 차이로 간주되었으며(*, P<0.05; **, P<0.01), 데이터는 평균 ± 표준오차(SEM)로 표시되었다.The statistics of the experiment were performed using one-way ANOVA, and the tukey's post hoc test was further performed for comparison between individual groups. P <0.05 was considered to be a statistically significant difference (*, P <0.05; **, P <0.01), and data were expressed as mean ± standard error (SEM).
실험결과Experiment result
도 1은 성인기(10주) 실험 쥐의 해마 절편에 증류수 vehicle을 처리한 후 Schaffer collateral 자극에 의해 CA1에서 생성되는 fEPSP를 측정한 결과이다. Figure 1 shows the results of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment of distilled water vehicle in hippocampus sections of adult rats (week 10).
도 1에서 확인 가능한 바와 같이, TBS 이후 fEPSP의 크기는 TBS 이전 baseline fEPSP의 크기와 상대적으로 비교하였을 때 (% of baseline) 크게 증가하여 시냅스가 장기적으로 강화되는 LTP가 유발되었음을 확인할 수 있다.As can be seen in Figure 1, the size of the fEPSP after TBS is significantly increased (% of baseline) compared to the size of the baseline fEPSP before TBS, it can be seen that LTP induced long-term strengthening of synapses.
그래프의 상단에 삽입된 fEPSP trace는 초기 20분 동안의 평균 fEPSP(검은색 선) 및 TBS 후 1시간 동안의 평균 fEPSP(붉은색 선)를 나타낸다.The fEPSP trace inserted at the top of the graph shows the average fEPSP (black line) for the initial 20 minutes and the average fEPSP (red line) for 1 hour after TBS.
도 2는 노년기(16개월) 실험 쥐의 해마 절편에 증류수 vehicle을 처리한 후 Schaffer collateral 자극에 의해 CA1에서 생성되는 fEPSP를 측정한 결과이다.Figure 2 is a result of measuring the fEPSP produced in CA1 by the Schaffer collateral stimulation after treatment of distilled water vehicle in hippocampus sections of the elderly rats (16 months).
도 2에서 확인 가능한 바와 같이, TBS 이후 fEPSP의 크기는 TBS 이전 baseline fEPSP의 크기와 상대적으로 비교하였을 때 (% of baseline) 소폭 증가하여 LTP가 유발되었음을 확인할 수 있으나, 정상 성인기(10주)에서 유발된 LTP와 비교하면 그 생성 정도가 적어 노년기에서의 인지저하 상태를 확인할 수 있다.As can be seen in Figure 2, the size of fEPSP after TBS is relatively increased (% of baseline) compared to the size of the baseline fEPSP before TBS can be confirmed that the LTP was induced, but induced in normal adulthood (10 weeks) Compared with LTP, the degree of generation is low, so it is possible to check the deterioration state in old age.
도 3은 노년기(16개월) 실험 쥐의 해마 절편에 증류수에 용해한 보이차 추출물(10μg/ml)을 처리한 후 Schaffer collateral 자극에 의해 CA1에서 생성되는 fEPSP를 측정한 결과이다.Figure 3 is a result of measuring the fEPSP produced in CA1 by Schaffer collateral stimulation after treatment with Bocha tea extract (10μg / ml) dissolved in distilled water in the hippocampus section of the experimental rats (16 months old age).
도 3에서 확인 가능한 바와 같이, TBS 이후 fEPSP의 크기는 TBS 이전 baseline fEPSP의 크기와 상대적으로 비교하였을 때 (% of baseline) 크게 증가하여 LTP가 유발되었음을 확인할 수 있다. As can be seen in Figure 3, the size of the fEPSP after TBS compared to the size of the baseline fEPSP before TBS (% of baseline) it can be seen that the LTP is significantly increased.
이처럼 보이차 추출물을 처리한 노년기의 해마에서 측정된 LTP는 증류수 vehicle을 처리한 노년기의 해마에서 측정한 LTP보다 크며, 정상 성인기(10주)와 비교하여 차이가 없는 정도 회복되어, 보이차 추출물에 의한 노인성 인지저하의 개선 효과를 확인할 수 있다.As such, LTP measured in old-age hippocampus treated with vocha tea extract was greater than LTP measured in old-time hippocampus treated with distilled water vehicle, and recovered to no difference compared to normal adulthood (10 weeks). It can confirm the improvement effect of cognitive deterioration by senescence.
위의 세 그룹에서, TBS 후 측정한 fEPSP 크기를 TBS 전 fEPSP의 크기와 상대적으로 비교한(% of baseline) 평균값을 막대그래프로 종합하여 도 4에 표시하였다. In the above three groups, the average value obtained by comparing the size of fEPSP measured after TBS with the size of fEPSP before TBS (% of baseline) is shown in FIG. 4.
도 4에서, 노년기(16개월) 해마에 vehicle을 처리한 그룹의 fEPSP는 성인기(10주) 해마에 vehicle을 처리한 그룹에서 측정한 fEPSP 보다 통계적으로 유의미하게 적어 노인성 인지저하 상태를 전기생리학적으로 확인하였다.In FIG. 4, the fEPSP of the group treated with vehicle in the elderly (16 months) hippocampus was statistically significantly less than the fEPSP measured in the group treated with vehicle in the adult (10 weeks) hippocampus, electrophysiologically. Confirmed.
한편, 노년기(16개월) 해마에 보이차 추출물을 처리한 그룹에서 측정한 fEPSP는 vehicle을 처리한 노년기(16개월) 그룹과 비교하여 통계적으로 유의미하게 증가하여 있을 뿐만 아니라, vehicle을 처리한 성인기(10주) 그룹과 통계적으로 다르지 않았다. 이는 보이차 추출물이 노인성 인지저하를 성인기 정상 수준으로 개선하는 효과가 있음을 전기생기학적으로 확인하였음을 의미한다.On the other hand, fEPSP measured in the group treated with the boy tea extract in the old age (16 months) hippocampus was statistically significantly increased compared to the old age (16 months) group treated with the vehicle. 10 weeks) was not statistically different from the group. This means that it has been confirmed electro-biologically that the ivory tea extract has an effect of improving senile deterioration to normal levels in adulthood.
이상 본 발명의 일부 구현 형태에 대해서 설명하였으나, 본 발명은 상술한 바와 같은 구현형태에 대해서만 한정되는 것이 아니라 본 발명의 요지를 벗어나지 않는 범위 내에서 수정 및 변형하여 실시할 수 있으며, 그러한 수정 및 변형이 가해진 형태 또한 본 발명의 기술적 사상에 속하는 것으로 이해되어야 한다.While some embodiments of the present invention have been described above, the present invention is not limited only to the above-described embodiments, but may be modified and modified without departing from the scope of the present invention, and such modifications and variations It is to be understood that this added form also belongs to the technical spirit of the present invention.

Claims (6)

  1. 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물.Pharmaceutical composition for the prevention or treatment of cognitive impairment due to aging comprising a tea extract as an active ingredient.
  2. 제 1 항에 있어서, The method of claim 1,
    상기 인지기능이 지각(perception), 기억(memory), 주의(attention), 언어 이해(speech comprehension), 언어 생성(speech generation), 독서 이해(reading comprehension), 심상 생성(creation of imagery), 학습(learning) 및 추리(reasoning)로 구성된 군에서 선택되는 것을 특징으로 하는, 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물.The cognitive function is perception, memory, attention, speech comprehension, speech generation, reading comprehension, creation of imagery, learning A pharmaceutical composition for preventing or treating cognitive impairment due to aging, characterized in that selected from the group consisting of learning and reasoning.
  3. 제 1 항에 있어서, The method of claim 1,
    상기 인지기능 장애가 알츠하이머병, 파킨슨병, 헌팅텅병, 타우병증 및 뇌졸중으로 구성된 군에서 선택되는 것을 특징으로 하는, 노화로 인한 인지기능 장애 예방 또는 치료용 약제학적 조성물.The cognitive impairment is selected from the group consisting of Alzheimer's disease, Parkinson's disease, hunting tongue disease, tau disease and stroke, pharmaceutical composition for preventing or treating cognitive impairment due to aging.
  4. 보이차 추출물을 유효성분으로 포함하는 노화로 인한 인지기능 장애 개선용 기능성 식품.Functional food for improving cognitive impairment due to aging, including the extract of black tea as an active ingredient.
  5. 제 1 항에 있어서, The method of claim 1,
    상기 인지기능이 지각(perception), 기억(memory), 주의(attention), 언어 이해(speech comprehension), 언어 생성(speech generation), 독서 이해(reading comprehension), 심상 생성(creation of imagery), 학습(learning) 및 추리(reasoning)로 구성된 군에서 선택되는 것을 특징으로 하는, 노화로 인한 인지기능 장애 개선용 기능성 식품.The cognitive function is perception, memory, attention, speech comprehension, speech generation, reading comprehension, creation of imagery, learning Functional food for improving cognitive impairment due to aging, characterized in that selected from the group consisting of learning and reasoning (reasoning).
  6. 제 1 항에 있어서, The method of claim 1,
    상기 인지기능 장애가 알츠하이머병, 파킨슨병, 헌팅텅병, 타우병증 및 뇌졸중으로 구성된 군에서 선택되는 것을 특징으로 하는, 노화로 인한 인지기능 장애 개선용 기능성 식품.The cognitive impairment is selected from the group consisting of Alzheimer's disease, Parkinson's disease, hunting tongue disease, tau disease and stroke, functional food for improving cognitive impairment due to aging.
PCT/KR2019/004230 2018-04-26 2019-04-09 Pharmaceutical composition for prevention or treatment of cognitive impairment due to aging comprising pu-erh tea extract as active ingredient WO2019208956A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0048727 2018-04-26
KR1020180048727A KR20190124579A (en) 2018-04-26 2018-04-26 Pharmaceutical Composition Comprising Pu'er Tea Extract for Preventing or Treating Aging-induced Cognitive Impairment

Publications (1)

Publication Number Publication Date
WO2019208956A1 true WO2019208956A1 (en) 2019-10-31

Family

ID=68294131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/004230 WO2019208956A1 (en) 2018-04-26 2019-04-09 Pharmaceutical composition for prevention or treatment of cognitive impairment due to aging comprising pu-erh tea extract as active ingredient

Country Status (2)

Country Link
KR (1) KR20190124579A (en)
WO (1) WO2019208956A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101856433A (en) * 2010-06-22 2010-10-13 马治中 Application of Puer tea in preparing dugs for preventing oxidative stress caused by immunosenescence or other relevant disease thereof
KR20110088715A (en) * 2010-01-29 2011-08-04 계명대학교 산학협력단 Compositions for anticancer comprising puer tea extract as an active ingredient
KR20120064299A (en) * 2010-12-09 2012-06-19 (주)아모레퍼시픽 Composition containing extract of fermentated tea for reducing lipid level

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110088715A (en) * 2010-01-29 2011-08-04 계명대학교 산학협력단 Compositions for anticancer comprising puer tea extract as an active ingredient
CN101856433A (en) * 2010-06-22 2010-10-13 马治中 Application of Puer tea in preparing dugs for preventing oxidative stress caused by immunosenescence or other relevant disease thereof
KR20120064299A (en) * 2010-12-09 2012-06-19 (주)아모레퍼시픽 Composition containing extract of fermentated tea for reducing lipid level

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUH, P.-D.: "Effects of pu-erh tea on oxidative damage and nitric oxide scavenging", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 52, no. 26, 2004, pages 8169 - 8176, XP055647756 *
KWON GU YOUNG: "Pu-erh tea, making your stomach comfortable and treating chronic diseases even though you drink a lot", GOYANG NEWS, 18 September 2017 (2017-09-18), pages 1 - 5, Retrieved from the Internet <URL:http://www.mygoyang.com/news/articleView.html?idxno=43869> *
LI, C.: "Pu-erh tea protects the nervous system by inhibiting the expression of metabotropic glutamate receptor 5", MOLECULAR NEUROBIOLOGY, vol. 54, 2017, pages 5286 - 8299, XP036287469 *

Also Published As

Publication number Publication date
KR20190124579A (en) 2019-11-05

Similar Documents

Publication Publication Date Title
KR101473017B1 (en) Senescence inhibitor
US20220023376A1 (en) Compositions for enhancing brain activity
JP6100692B2 (en) Sleep quality improver
US20210128664A1 (en) Agent for Activating Astrocyte Glucose Metabolism
EP2859896B1 (en) Pharmaceutical compositions for the treatment of muscular disorders
US7514104B2 (en) Composition containing an extract of pericarpium zanthoxyli for protecting brain cells and improving memory
KR102011033B1 (en) Composition for enhancing cognitive function comprising tea extraction which has modified amount of ingredients
US11596664B2 (en) Plant extracts made of Sideritis and use thereof to boost cognitive performance
US11376294B2 (en) Mangiferin-containing compositions for improving sports performance
CN111493315A (en) Memory-improving antioxidant composition and application thereof
WO2019208956A1 (en) Pharmaceutical composition for prevention or treatment of cognitive impairment due to aging comprising pu-erh tea extract as active ingredient
KR101071684B1 (en) Compositions for improving memory power and learning ability comprising extract from illicium verum as active ingredient
JP7281276B2 (en) Cognitive function improver
KR102282883B1 (en) Composition for preventing and/or treating a degenerative brain disease comprising as an active ingredient an extract of Cimicifuga dahurica, a fraction thereof, or a compound derived from Cimicifuga dahurica
WO2021225343A1 (en) Composition for preventing or treating cognitive disorder, comprising iris lactea extract
JP2019006717A (en) Oral sleep improver
KR20200122934A (en) Pharmaceutical composition for improving memory and learning ability and health functional food
US8128969B2 (en) Hypoglycemic composition containing acacia bark derivative
KR20230106932A (en) Composition for protection of brain neuronal cells comprising fermented garlic
WO2012138190A2 (en) Composition containing jetbead extracts
KR20240064195A (en) Composition for improving sense of smell, memory and cognitive function, which contains extract of aloe vera extract as an active ingredient
KR20240006284A (en) A composition for improving, preventing and treating of cognitive impairment containing Eriobotrya japonica fruit extract
KR20220059650A (en) A composition for the prevention or treatment of depression, stress or memory malfunctions containing Erythronium japonicum extract
WO2017130638A1 (en) Agent for activating astrocyte glucose metabolism
JP2022097984A (en) Mental condition improving agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19793730

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19793730

Country of ref document: EP

Kind code of ref document: A1